Mark E. Molitch

36.5k total citations · 12 hit papers
326 papers, 20.0k citations indexed

About

Mark E. Molitch is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Epidemiology. According to data from OpenAlex, Mark E. Molitch has authored 326 papers receiving a total of 20.0k indexed citations (citations by other indexed papers that have themselves been cited), including 270 papers in Endocrinology, Diabetes and Metabolism, 73 papers in Surgery and 38 papers in Epidemiology. Recurrent topics in Mark E. Molitch's work include Pituitary Gland Disorders and Treatments (145 papers), Growth Hormone and Insulin-like Growth Factors (119 papers) and Adrenal and Paraganglionic Tumors (54 papers). Mark E. Molitch is often cited by papers focused on Pituitary Gland Disorders and Treatments (145 papers), Growth Hormone and Insulin-like Growth Factors (119 papers) and Adrenal and Paraganglionic Tumors (54 papers). Mark E. Molitch collaborates with scholars based in United States, Germany and Canada. Mark E. Molitch's co-authors include George L. Bakris, Шломо Мелмед, Mary Lee Vance, Laurence Katznelson, Edward R. Laws, David R. Clemmons, M. Hassan Murad, John Wass, George R. Merriam and Mary P. Gillam and has published in prestigious journals such as New England Journal of Medicine, JAMA and Circulation.

In The Last Decade

Mark E. Molitch

317 papers receiving 19.3k citations

Hit Papers

Acromegaly: An Endocrine ... 2006 2026 2012 2019 2014 2006 2019 2014 2014 250 500 750 1000

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Mark E. Molitch 13.4k 5.6k 3.0k 2.7k 2.1k 326 20.0k
Michel Marre 8.7k 0.6× 3.3k 0.6× 2.3k 0.8× 1.9k 0.7× 3.9k 1.9× 423 17.2k
Janet B. McGill 9.1k 0.7× 3.4k 0.6× 2.2k 0.7× 1.4k 0.5× 2.4k 1.2× 236 16.2k
James H. Warram 6.4k 0.5× 3.5k 0.6× 5.2k 1.7× 2.0k 0.7× 3.5k 1.7× 190 17.3k
Andrzej S. Królewski 5.8k 0.4× 3.2k 0.6× 5.3k 1.8× 1.6k 0.6× 3.1k 1.5× 190 15.7k
Barry I. Freedman 3.2k 0.2× 1.8k 0.3× 6.2k 2.1× 1.7k 0.6× 3.3k 1.6× 420 16.3k
François Cambien 7.0k 0.5× 3.2k 0.6× 840 0.3× 2.1k 0.8× 3.9k 1.9× 229 20.8k
Enzo Bonora 11.2k 0.8× 3.7k 0.7× 1.6k 0.5× 8.4k 3.2× 5.2k 2.5× 356 25.1k
Bruce A. Perkins 7.3k 0.5× 3.8k 0.7× 2.6k 0.9× 658 0.2× 1.7k 0.8× 253 14.4k
George Jerums 4.6k 0.3× 1.3k 0.2× 4.8k 1.6× 921 0.3× 2.1k 1.0× 285 13.4k
Lise Tarnow 5.2k 0.4× 1.8k 0.3× 2.9k 1.0× 903 0.3× 2.1k 1.0× 279 12.1k

Countries citing papers authored by Mark E. Molitch

Since Specialization
Citations

This map shows the geographic impact of Mark E. Molitch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark E. Molitch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark E. Molitch more than expected).

Fields of papers citing papers by Mark E. Molitch

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark E. Molitch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark E. Molitch. The network helps show where Mark E. Molitch may publish in the future.

Co-authorship network of co-authors of Mark E. Molitch

This figure shows the co-authorship network connecting the top 25 collaborators of Mark E. Molitch. A scholar is included among the top collaborators of Mark E. Molitch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark E. Molitch. Mark E. Molitch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Limonte, Christine P., Xiaoyu Gao, Ionut Bebu, et al.. (2024). Longitudinal Trajectories of Biomarkers of Kidney Tubular Function in Type 1 Diabetes. Kidney International Reports. 9(5). 1406–1418. 1 indexed citations
2.
Yuen, Kevin C.J., Wenyu Huang, Maria Fleseriu, et al.. (2024). 9191 Real-world Biochemical And Symptoms Outcomes With Oral Octreotide: Management Of Acromegaly (MACRO) Registry Experience. Journal of the Endocrine Society. 8(Supplement_1).
3.
Geer, Eliza B., Wenyu Huang, Murray B. Gordon, et al.. (2023). SAT622 Matched Physician- And Patient-reported Responses Of Acromegaly Symptom Control: Comparisons From The Macro Registry. Journal of the Endocrine Society. 7(Supplement_1).
4.
Molitch, Mark E., Mark Tripputi, Andrew S. Levey, et al.. (2023). Effects of metformin and intensive lifestyle interventions on the incidence of kidney disease in adults in the DPP/DPPOS. Journal of Diabetes and its Complications. 37(9). 108556–108556. 3 indexed citations
5.
Nachtigall, Lisa B., Maria Fleseriu, Murray B. Gordon, et al.. (2021). Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results. Pituitary. 24(6). 943–953. 15 indexed citations
6.
Perkins, Bruce A., Ionut Bebu, Ian H. de Boer, et al.. (2019). Risk Factors for Kidney Disease in Type 1 Diabetes. Diabetes Care. 42(5). 883–890. 88 indexed citations
7.
Chamberlin, Michael J., et al.. (2015). Qualitative Analysis of Key Informant Interviews to Establish Barriers And Solutions for Diabetes Care In a Rural Bolivian Clinic. 5(3). 1 indexed citations
8.
Molitch, Mark E.. (2013). Current state of type 2 diabetes management.. PubMed. 19(8 Suppl). S136–42. 9 indexed citations
9.
Freda, Pamela U., Albert Beckers, Laurence Katznelson, et al.. (2011). Pituitary Incidentaloma: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. 96(4). 894–904. 356 indexed citations
10.
Мелмед, Шломо, Annamaria Colao, Ariel L. Barkan, et al.. (2009). Guidelines for Acromegaly Management: An Update. The Journal of Clinical Endocrinology & Metabolism. 94(5). 1509–1517. 549 indexed citations breakdown →
12.
13.
Gillam, Mary P., Hugo Fideleff, Hugo Boquete, & Mark E. Molitch. (2004). Prolactin excess: treatment and toxicity.. PubMed. 2 Suppl 1. 108–14. 10 indexed citations
14.
Steffes, Michael W., Mark E. Molitch, Blanche M. Chavers, Patricia A. Cleary, & John M. Lachin. (2003). Sustained effect of intensive treatment of type 1 diabetes mellitus on the development and progression of diabetic nephropathy in epidemiology of diabetes interventions and complications (EDIC) study.. JAMA. 290(16). 41 indexed citations
15.
Klibanski, Anne, Ken K. Y. Ho, Pamela U. Freda, et al.. (2001). State-of-the-Art Strategies for the Diagnosis and Management of Acromegaly. The Endocrinologist. 11(3). 223–232. 4 indexed citations
16.
Molitch, Mark E.. (1999). Advances in pituitary tumor therapy. 3 indexed citations
17.
Molitch, Mark E., R. L. Elton, Richard E. Blackwell, et al.. (1986). Bromocriptine as Primary Therapy for Prolactin-Secreting Macroadenomas. Obstetrical & Gynecological Survey. 41(1). 48–49. 2 indexed citations
18.
Molitch, Mark E., R. L. Elton, Richard E. Blackwell, et al.. (1985). Bromocriptine as Primary Therapy for Prolactin-Secreting Macroadenomas. Obstetrical & Gynecological Survey. 40(10). 649–650. 1 indexed citations
19.
Wolpert, Samuel M., Mark E. Molitch, James A. Goldman, & James B. Wood. (1984). Size, Shape, and Appearance of the Normal Female Pituitary Gland. American Journal of Neuroradiology. 5(3). 263–267. 19 indexed citations
20.
McCarron, David A., et al.. (1978). The effect of chronic beta-adrenergic blockade on parathormone (PTH) secretion in subjects with essential hypertension. Clinical research. 26(2). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026